DAEJEON, South Korea, July
7, 2020 /PRNewswire/ -- ILIAS
Biologics Inc. (the "Company" or "ILIAS"), a global leader in
exosome-based therapeutics, announced today that the Company has
been granted a key exosome engineering patent by the United States
Patent and Trademark Office (USPTO).
A patent for ILIAS's exosome engineering was previously granted
in South Korea by the Korean
Intellectual Property Office (KIPO), and the Company has applied
for the patents in 7 other countries as well. This latest patent is
integral to the Company's EXPLOR®
(EXosome engineering for Protein Loading via Optically Reversible
protein–protein interaction) platform technology as well as
the Exo-Target® products, as the patent covers not only EXPLOR®
technology but also its application for various therapeutic cargo
proteins developed by ILIAS for loading into exosomes.
EXPLOR® technology is a novel protein-loading method that
enables active loading of large therapeutic cargo proteins into the
lumen of exosomes—nanosized extracellular vesicles—through cellular
biogenesis processes. This process involves controllable and
reversible detachment of cargo proteins from the membrane of
exosomes once they load into exosomes, which increases the
efficiency of delivery of payload proteins into the cytoplasm or
nucleus of target cells. While exosomes have been actively studied
as novel therapeutic vehicles for intracellular drug delivery, the
controllable loading of therapeutic cargo proteins as free forms in
the exosomal lumen has remained a technical hurdle. ILIAS's
technology provides a unique solution to overcome this
challenge.
"This is a major accomplishment that allows the development
of engineered exosomes as a new class of
therapeutics," says Dr Chulhee
Choi, ILIAS's Chief Executive Officer. "We are very
pleased to see that by granting this patent, the United States patent office has recognized
ILIAS's innovations in the exosome engineering space. By applying
this technology to numerous intracellular target proteins with
therapeutic potential, we will be able to achieve so many
breakthroughs that couldn't be accomplished before."
ILIAS is developing various pipelines, with its
anti-inflammation programs being the most advanced. Recently, the
Company published promising preclinical data on its lead
therapeutic candidate, ILB-202, in Science Advances, and is
planning to start its first-in-human clinical trial in the year
2021.
About ILIAS Biologics Inc.
ILIAS Biologics Inc. (previously Cellex Life Sciences, Inc.) was
established in 2015 in South Korea
to develop exosome-based therapeutics. ILIAS is currently
developing various pipelines including inflammatory diseases and
oncology. To learn more about ILIAS Biologics Inc, visit our
website at www.iliasbio.com.
View original
content:http://www.prnewswire.com/news-releases/ilias-biologics-granted-key-patent-for-exosome-based-drug-delivery-system-in-the-united-states-301088742.html
SOURCE ILIAS Biologics Inc.